DR. VINCENT GIAMPAPA, MD, FACS
Founder, Global Foundation for Human Aging Research
Dr. Giampapa is a Board Certified Surgeon, Certified Anti-Aging Medical Doctor, and Fellow of the American College of Surgeons. He is the Director of the Plastic Surgery Center Internationale in Montclair, New Jersey, Co-founder of the American Academy of Anti-Aging Medicine, and Co-founder of Healthycell®.
His university-based anti-aging research has earned him a Gusi Peace Prize, a Nobel Prize nomination, as well as a keynote speaking position at the Second International Vatican Adult Stem Cell Conference at the Vatican in Rome.
He is the author of the first and only medical textbook on Anti-Aging Medicine and Age Management for Aesthetic Surgeons. He also authored 5 consumer titles on the topic including; Breaking the Aging Code (Basic Health Publications) and The Anti-Aging Solution: 5 Simples Steps to Looking and Feeling Young (Wiley), The Gene Makeover, The 21st Century Anti-Aging Breakthrough, Quantum Longevity, and Pro-Hormone Nutrition-Optimum Aging & Maximum Health Span with Nature’s Hormone-Enhancing Nutrients.
Dr. Giampapa has served as Research Fellow for such other prestigious institutes as Columbia Presbyterian Medical Center in New York City and was the Director of Microsurgery and Re-plantation Surgery at the University of Medicine and Dentistry of New Jersey. He is published in numerous academic journals including the Annals of Plastic Surgery, the Journal of Plastic Reconstructive Surgery, The Journal of Reconstructive Microsurgery and The Journal of Anti-Aging Medicine.
Dr. Giampapa is internationally recognized as an innovator in new cosmetic and surgical techniques and instrumentation as well as, a pioneer in the field of anti-aging medicine. He has been awarded over a dozen patents from the United States Government for unique cell culture delivery techniques, as well as, new drug delivery systems, and surgical instrument designs.
Dr. Giampapa has been featured in myriad national media including CNN, Fox News, Geraldo Rivera, Joan Rivers, Phil Donahue, Anderson Cooper, and most recently on Discovery Science Channel as an expert on Stem Cell Universe hosted by Steven Hawking.
He has worked as a consultant to NASA, Allergan Medical, Medicis Pharmaceutical Corporation, Sanofi-Aventus, NeoStem, and still serves as a consultant to American CryoStem (CRYO), Optigenex, Jeunesse Global, and MHP.
He received his M.D. degree from Mt. Sinai Medical School in New York, New York and continued his medical training in plastic surgery. Upon completion of his plastic surgical training, he completed a year of microsurgery and hand fellowship at New York University Medical Center.
Advisor, Global Foundation for Human Aging Research
Doug is the co-founder and CEO of Healthycell and co-founder / lead developer of the Dorada real estate development in Costa Rica. He graduated from Cornell University in 2005 and serves the Global Foundation for Human Aging Research in an advisory capacity.
Dr. Urzola’s passion is his work. He has made a significant commitment to patient care. He gives thorough his consultations with the emphasis of quality not quantity. Patients can be assured that they will get the accessibility and attention they deserve. He maintains an open and unhurried pace. “In this way, I can customize the procedure to fit the individual needs of each patient. My practice has grown because I treat my patients with the utmost care and yield cosmetic results, that highlight the person’s natural beauty.”
If Dr. Victor Urzola’s work can be summarized in a single concept, it would be his meticulous ATTENTION TO DETAILS in every aspect. Dr. Urzola personally evaluates each patient and allows an ample time during consultations for a comprehensive discussion of all treatment options.
In addition of being up to date with the latest developments in plastic surgery, Dr. Urzola continually addresses his patient’s growing needs for aesthetic integrity in a highly efficient manner.
This skilled plastic surgeon offers the spectrum of advanced procedures including liposuction, body contouring, and facial cosmetic surgery. Dr Urzola’s comprehensive laser liposuction menu includes large-volume liposuction, facial liposuction, liposuction to the usual targets such as hips, abdomen and thighs, as well as liposuction to the calves, ankles, arms, and neck.
While breast enhancement, breast reduction, gynecomastia correction (male breast reduction), facelifts, and eyelifts are his most highly requested procedures. He also helps to refresh his patient’s appearance, offering minimally invasive options that include laser peels, and injectables such as Botulinum toxin (Botox) and Hyaluronic acid fillers.
Dr. Urzola is very accessible, so you may contact him with any questions you have.
Eric Donsky has over 25 years experience in building very progressive cleantech and life science companies as a founder and senior manager. Eric was the founding CEO of TearLab Corporation, a publicly traded, in-vitro diagnostics company (NASDAQ:TEAR) that has successfully commercialized one of the world’s first point-of-care, nanofluidic lab-on-a-chip platforms. The Company’s patented TearLab™ system is capable of measuring disease markers in tears for the rapid diagnosis of eye diseases. The TearLab™ has obtained FDA approval, CLIA Waiver, CE Mark, broad reimbursement in the United States, and is marketed in over 25 countries worldwide. Shortly after Eric’s departure, Tearlab’s market capitalization reached $500M. Eric was also the founding Chairman of Singularis, a biotechnology company commercializing a highly lubricating, recombinant protein for a number of therapeutic indications, including Dry Eye Disease, vaginal atrophy, knee osteoarthritis and interstitial cystitis. The Company has completed several strategic alliances and has its first product in clinical trials. The Company recently completed a licensing transaction with Novartis that includes $500M in payments plus royalties on sales. Eric was the founding CEO of Applied CarboChemicals, Inc. (“ACC”), one of the first synthetic biology companies developing processes capable of manufacturing chemicals and plastics from renewable carbon. ACC, renamed Bioamber (NYSE:BIOA), has developed a proprietary process capable of economically manufacturing succinic acid through fermentation at large scale using a genetically-engineered yeast strain. Succinic acid serves as a chemical intermediate for the synthesis of a vast range of derivative chemistries that function as detergent additives, monomers, polymers, coatings, solvents, among many other applications. BioAmber has built a $141M manufacturing facility in Sarnia, Canada and has formed strategic partnerships with DuPont, Cargill, Lanxess, Mitsubishi and Mitsui. The Company is publicly traded on the NYSE. Mr. Donsky graduated from Boston University in 1987 with a B.S. in Business Administration.
Eric is currently the CEO of Axium Nano, an advanced materials company that has developed nanomanufacturing processes capable of producing nanoscale composites thousands of times faster than conventional nanofabrication systems. Axium is initially targeting the $40B global market for lithium ion (Li-ion) battery materials. The Company’s silicon graphene anode (electrode) increases the energy storage capacity of a Li-ion battery by 40%. The Company has a full pipeline of battery materials to improve the performance and safety of Li-ion batteries and also materials that could facilitate the commercialization of next generation battery chemistries that store far more energy than Li-ion and could unlock the possibilities of mobility and electric vehicles.